Federal Register / Vol. 89, No. 213 / Monday, November 4, 2024 / Notices 87727 

involve reference to staff and consultant 

critiques of research proposals. 

Discussions will deal with scientific 

merit of each proposal and 

qualifications of personnel conducting 

the studies, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Additionally, premature disclosure of 

research information could significantly 

obstruct implementation of proposed 

agency action regarding the research 

proposals. As provided by Public Law 

92–463 subsection 10(d), and as 

amended by Public Law 94–409, closing 

the committee meeting is in accordance 

with Title 5 U.S.C. 552b(c) (6) and 

(9)(B). 

The objective of the Board is to 

provide for the fair and equitable 

selection of the most meritorious 

research projects for support by VA 

research funds and to offer advice for 

research program officials on program 

priorities and policies. The ultimate 

objective of the Board is to ensure the 

high quality and mission relevance of 

VA’s legislatively mandated Biomedical 

Laboratory and Clinical Science 

Research and Development programs. 

Board members advise the Directors 

of the Biomedical Laboratory and 

Clinical Sciences Research Services and 

the Chief Research and Development 

Officer on the scientific and technical 

merit, mission relevance, and protection 

of human subjects of Biomedical 

Laboratory and Clinical Sciences 

Research and Development proposals. 

The Board does not consider grants, 

contracts, or other forms of extramural 

research. 

Members of the public may attend the 

open portion of the meeting. The time 

limited agenda does not enable public 

comments or presentations. To attend 

the open portion of the meeting (3–3:30 

p.m. EDT), the public may join by 

dialing the phone number 1–404–397– 

1596 and entering the meeting number 

(access code): 2823 274 3705. Public 

comments accepted during the open 

portion of the meeting and public 

stakeholders who want to speak to the 

committee will be afforded three 

minutes during the public comment 

period. These stakeholders must notify 

the DFO of their intention to speak to 

the committee. 

Written public comments must be 

sent to Michael R. Burgio, Ph.D., 

Designated Federal Officer, Advisory 

Committee Management Office, 811 

Vermont Avenue NW, Room 4342A, 

Washington, DC 20006, or to 

Michael.Burgio@va.gov, at least five 

days before the meeting. The written 

public comments will be shared with 

the Board members. The public may not 

attend the closed portion of the meeting 

as disclosure of research information 

could significantly obstruct 

implementation of proposed agency 

action regarding the research proposals 

(per Pub. L. 92–463 subsection 10(d), as 

amended by Pub. L. 94–409, closing the 

committee meeting is in accordance 

with 5 U.S.C. 552b(c) (6) and (9)(B)). 

Dated: October 29, 2024. 

LaTonya L. Small, 

Federal Advisory Committee Management 

Officer. 

[FR Doc. 2024–25538 Filed 11–1–24; 8:45 am] 

BILLING CODE 8320–01–P 

DEPARTMENT OF VETERANS 

AFFAIRS 

Joint Biomedical Laboratory Research 

and Development and Clinical Science 

Research and Development Services 

Scientific Merit Review Board, 

AMENDED, Notice of Meeting 

The Department of Veterans Affairs 

(VA) gives notice under the Federal 

Advisory Committee Act, 5 U.S.C. 

ch.10, that a meeting of the Joint 

Biomedical Laboratory Research and 

Development and Clinical Science 

Research and Development Services 

Scientific Merit Review Board will be 

held January 7, 2025, via WebEx. The 

meeting will be held between 3 and 5 

p.m. EDT. The meeting will be closed to 

the public from 3:30–5 p.m. EDT for 

scientific review and the discussion, 

examination, and reference to the 

research applications. Discussions will 

involve reference to staff and consultant 

critiques of research proposals. 

Discussions will deal with scientific 

merit of each proposal and 

qualifications of personnel conducting 

the studies, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Additionally, premature disclosure of 

research information could significantly 

obstruct implementation of proposed 

agency action regarding the research 

proposals. As provided by Public Law 

92–463 subsection 10(d), and as 

amended by Public Law 94–409, closing 

the committee meeting is in accordance 

with 5 U.S.C. 552b(c)(6) and (9)(B). 

The objective of the Board is to 

provide for the fair and equitable 

selection of the most meritorious 

research projects for support by VA 

research funds and to offer advice for 

research program officials on program 

priorities and policies. The ultimate 

objective of the Board is to ensure the 

high quality and mission relevance of 

VA’s legislatively mandated Biomedical 

Laboratory and Clinical Science 

Research and Development programs. 

Board members advise the Directors 

of the Biomedical Laboratory and 

Clinical Sciences Research Services and 

the Chief Research and Development 

Officer on the scientific and technical 

merit, mission relevance, and protection 

of human subjects of Biomedical 

Laboratory and Clinical Sciences 

Research and Development proposals. 

The Board does not consider grants, 

contracts, or other forms of extramural 

research. 

Members of the public may attend the 

open portion of the meeting. The time 

limited agenda does not enable public 

comments or presentations. To attend 

the open portion of the meeting (3–3:30 

p.m. EDT), the public may join by 

dialing the phone number 1–404–397– 

1596 and entering the meeting number 

(access code): 2823 274 3705. These 

stakeholders must notify the DFO of 

their intention to speak to the 

committee. 

Written public comments must be 

sent to Michael R. Burgio, Ph.D., 

Designated Federal Officer, Advisory 

Committee Management Office, 811 

Vermont Avenue NW, Room 4342A, 

Washington, DC 20006, or to 

Michael.Burgio@va.gov, at least five 

days before the meeting. The written 

public comments will be shared with 

the Board members. The public may not 

attend the closed portion of the meeting 

as disclosure of research information 

could significantly obstruct 

implementation of proposed agency 

action regarding the research proposals 

(per Pub. L. 92–463 subsection 10(d), as 

amended by Public Law 94–409, closing 

the committee meeting is in accordance 

with 5 U.S.C. 552b(c)(6) and (9)(B). 

Dated: October 29, 2024. 

LaTonya L. Small, 

Federal Advisory Committee Management 

Officer. 

[FR Doc. 2024–25550 Filed 11–1–24; 8:45 am] 

BILLING CODE 8320–01–P 


lotter on DSK11XQN23PROD with NOTICES1